Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000057177 | SCV001101731 | likely benign | not provided | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000057177 | SCV001153657 | likely benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | NEFH: BS2 |
Ambry Genetics | RCV002408558 | SCV002715344 | likely benign | Inborn genetic diseases | 2019-09-06 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003915022 | SCV004728353 | likely benign | NEFH-related condition | 2020-03-16 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Epithelial Biology; Institute of Medical Biology, |
RCV000057177 | SCV000088290 | not provided | not provided | no assertion provided | not provided | ||
Genome |
RCV000057177 | SCV000607161 | not provided | not provided | no assertion provided | phenotyping only | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. |